ATE371191T1 - Die verwendung von dem a3 adenosin rezeptor als marker eines krankheitszustandes - Google Patents

Die verwendung von dem a3 adenosin rezeptor als marker eines krankheitszustandes

Info

Publication number
ATE371191T1
ATE371191T1 AT03758621T AT03758621T ATE371191T1 AT E371191 T1 ATE371191 T1 AT E371191T1 AT 03758621 T AT03758621 T AT 03758621T AT 03758621 T AT03758621 T AT 03758621T AT E371191 T1 ATE371191 T1 AT E371191T1
Authority
AT
Austria
Prior art keywords
adenosine receptor
marker
disease condition
expression level
disease
Prior art date
Application number
AT03758621T
Other languages
German (de)
English (en)
Inventor
Pnina Fishman
Lea Madi
Yehuda Sara Bar
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Application granted granted Critical
Publication of ATE371191T1 publication Critical patent/ATE371191T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03758621T 2002-10-22 2003-10-21 Die verwendung von dem a3 adenosin rezeptor als marker eines krankheitszustandes ATE371191T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42003802P 2002-10-22 2002-10-22

Publications (1)

Publication Number Publication Date
ATE371191T1 true ATE371191T1 (de) 2007-09-15

Family

ID=32176505

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03758621T ATE371191T1 (de) 2002-10-22 2003-10-21 Die verwendung von dem a3 adenosin rezeptor als marker eines krankheitszustandes

Country Status (7)

Country Link
US (1) US20040137477A1 (fr)
EP (1) EP1554583B1 (fr)
JP (1) JP2006503574A (fr)
AT (1) ATE371191T1 (fr)
AU (1) AU2003274648A1 (fr)
DE (1) DE60315863T2 (fr)
WO (1) WO2004038419A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113828A1 (fr) * 2004-05-14 2005-12-01 King Pharmaceuticals Research & Development, Inc. Procedes de diagnostic et de pronostic de tumeurs solides et de melanomes
US20080051365A1 (en) * 2004-12-02 2008-02-28 Can-Fite Biopharma Ltd. Treatment of Inflammation
EP1817079B1 (fr) * 2004-12-02 2008-07-30 Can-Fite Biopharma Ltd. Traitement anti-inflammatoire
US20080292637A1 (en) * 2005-11-30 2008-11-27 Pnina Fishman Therapeutic Uses of A3 Adenosine Receptor Antibodies
DK1983990T3 (da) 2006-01-26 2011-07-11 Us Gov Health & Human Serv Allosteriske A3-adenosin-receptormodulatorer
WO2008056361A1 (fr) * 2006-11-09 2008-05-15 Can-Fite Biopharma Ltd. Marqueur biologique du psoriasis
US9102698B2 (en) 2007-03-14 2015-08-11 Can-Fite Biopharma Ltd. Process for the synthesis of IB-MECA
JP2012500255A (ja) * 2008-08-19 2012-01-05 ユニバーシテイト ライデン Ａ３アデノシン受容体アロステリックモジュレーター

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543291A (en) * 1993-01-29 1996-08-06 Dana Farber Cancer Institute Method of detecting carcinoma
US6063376A (en) * 1995-01-13 2000-05-16 Human Genome Sciences, Inc. Human deoxycytidine kinase 2
DE69739276D1 (de) * 1996-04-05 2009-04-09 Antonio Giordano Methoden zur diagnose und prognose von krebs
WO2000002861A1 (fr) * 1998-07-10 2000-01-20 The United States Of America, Represented By Secretary, Department Of Health And Human Services Antagonistes du recepteur de l'adenosine a¿3?
US6448253B1 (en) * 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

Also Published As

Publication number Publication date
WO2004038419A1 (fr) 2004-05-06
DE60315863D1 (de) 2007-10-04
JP2006503574A (ja) 2006-02-02
US20040137477A1 (en) 2004-07-15
DE60315863T2 (de) 2008-05-15
EP1554583B1 (fr) 2007-08-22
EP1554583A1 (fr) 2005-07-20
AU2003274648A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
DE602006012816D1 (de) Tifizierung von zellulären folat vitamin rezeptoren
TW200710705A (en) Touch location determination using bending mode sensors and multiple detection techniques
ATE426662T1 (de) Feedback resistante mevalonate kinase
CY1110116T1 (el) Νευροεκφυλιστικοι δεικτες για καταθλιψη
NO20084354L (no) Fremgangsmate og system for styring av boreretning ved bruk av retningsfolsomme resistivitetsmalinger
DE602005024268D1 (de) System und verfahren zum operieren in einem virtuellen 3d-raum
AR040748A1 (es) Un metodo y un sistema para posicionar unidades moviles utilizando mediciones de angulo
WO2006134390A3 (fr) Methode destinee a diagnostiquer une maladie neurodegenerative
ATE371191T1 (de) Die verwendung von dem a3 adenosin rezeptor als marker eines krankheitszustandes
ATE391284T1 (de) Verwendung von oberflächenmesssonden
EA200600197A1 (ru) Получение производных соединения 1,3-дифенилпроп-2-ен-1-он
PL2021794T3 (pl) Zastosowanie białka S100A 12 jako markera raka okrężnicy i odbytnicy
ATE403656T1 (de) Xanthinderivate als a2b- adenosinrezeptorantagonisten
BRPI0607016A2 (pt) marcadores polipeptìdicos para o diagnóstico de cáncer de próstata
BRPI0408884A (pt) método para determinar propriedades de um corpo sedimentário a partir da espessura e da distribuição de tamanho de grão em um ponto dentro do corpo
ATE447174T1 (de) Verfahren zum direkten nachweis einzelner methotrexatmetabolite
ATE365327T1 (de) Verfahren zum nachweis von zelltod mittels cytochrom c.
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
DK1791973T3 (da) DOT1-histonmethyltransferaser som et target til at identificere terapeutiske midler mod leukæmi
WO2006105949A3 (fr) Procede pour determiner l'occupation d'un espace
WO2006017748A3 (fr) Materiaux et procedes pour identifier des agents anti-schizophreniques
WO2005002414A3 (fr) Determination d'un pronostic chez des patients atteints du sarcome d'ewing au moyen d'un profilage genetique
DK0646182T3 (da) Fremgangsmåde til påvisning af neoplastiske sygdomme
ATE391115T1 (de) Verfahren zur herstellung von diketenacetalen
ATE466958T1 (de) Klassifizierung von kolonkrebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties